[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CN110520425A - EOC315 Mod.I晶型化合物及其制备方法 - Google Patents

EOC315 Mod.I晶型化合物及其制备方法 Download PDF

Info

Publication number
CN110520425A
CN110520425A CN201880024765.5A CN201880024765A CN110520425A CN 110520425 A CN110520425 A CN 110520425A CN 201880024765 A CN201880024765 A CN 201880024765A CN 110520425 A CN110520425 A CN 110520425A
Authority
CN
China
Prior art keywords
compound
solvent
eoc315
eoc315mod
crystalline form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880024765.5A
Other languages
English (en)
Other versions
CN110520425B (zh
Inventor
李合亭
王德强
常伟
于洪瑞
邹晓明
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taizhou Eoc Pharma Co ltd
Original Assignee
Taizhou Eoc Pharma Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taizhou Eoc Pharma Co ltd filed Critical Taizhou Eoc Pharma Co ltd
Publication of CN110520425A publication Critical patent/CN110520425A/zh
Application granted granted Critical
Publication of CN110520425B publication Critical patent/CN110520425B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明涉及一种4‑(4‑氯苯胺基)‑7‑(2‑甲氨基羰基‑4‑氧甲基)吡啶基呋喃并[2,3‑d]哒嗪甲磺酸盐(EOC315)的Mod.I晶型化合物的制备方法、晶型表征及其药物用途。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201880024765.5A 2017-04-13 2018-04-03 EOC315 Mod.I晶型化合物及其制备方法 Active CN110520425B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710239073.XA CN107129502B (zh) 2017-04-13 2017-04-13 EOC315 Mod.I晶型化合物及其制备方法
CN201710239073X 2017-04-13
PCT/CN2018/081660 WO2018188495A1 (zh) 2017-04-13 2018-04-03 EOC315 Mod.I晶型化合物及其制备方法

Publications (2)

Publication Number Publication Date
CN110520425A true CN110520425A (zh) 2019-11-29
CN110520425B CN110520425B (zh) 2023-04-14

Family

ID=59715717

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201710239073.XA Active CN107129502B (zh) 2017-04-13 2017-04-13 EOC315 Mod.I晶型化合物及其制备方法
CN201880024765.5A Active CN110520425B (zh) 2017-04-13 2018-04-03 EOC315 Mod.I晶型化合物及其制备方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201710239073.XA Active CN107129502B (zh) 2017-04-13 2017-04-13 EOC315 Mod.I晶型化合物及其制备方法

Country Status (8)

Country Link
US (2) US10954246B2 (zh)
EP (1) EP3613746B1 (zh)
JP (1) JP2020516685A (zh)
KR (1) KR20190137116A (zh)
CN (2) CN107129502B (zh)
AU (1) AU2018252643A1 (zh)
CA (1) CA3059455A1 (zh)
WO (1) WO2018188495A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089377A1 (en) * 2020-10-26 2022-05-05 Taizhou Eoc Pharma Co., Ltd. Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法
US20240294537A1 (en) * 2021-07-07 2024-09-05 Teva Pharmaceuticals International Gmbh SOLID STATE FORMS OF 4-[[4-(4-CHLOROANILINO)FURO[2,3-d]PYRIDAZIN-7-yl]OXYMETHYL]-N-METHYLPYRIDINE-2-CARBOXAMIDE AND SALT THEREOF

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420879A (zh) * 1999-09-28 2003-05-28 美国拜尔公司 具有血管生成抑制活性的取代的吡啶和哒嗪
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
CN104804008A (zh) * 2015-03-27 2015-07-29 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
CN107129502B (zh) * 2017-04-13 2022-08-05 泰州亿腾景昂药业股份有限公司 EOC315 Mod.I晶型化合物及其制备方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1420879A (zh) * 1999-09-28 2003-05-28 美国拜尔公司 具有血管生成抑制活性的取代的吡啶和哒嗪
WO2007118602A1 (en) * 2006-04-15 2007-10-25 Bayer Healthcare Ag Compounds for treating pulmonary hypertension
CN104804008A (zh) * 2015-03-27 2015-07-29 亿腾药业（泰州）有限公司 一种工业化生产甲磺酸特拉替尼的方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALSINA M，等: "Clinical and pharmacodynamic (PD) results of TEL0805 trial: A phase II study of telatinib (TEL) in combination with capecitabine (X) and cisplatin (P) as first-line treatment in patients (pts) with advanced gastric or gastroesophageal junction (GEJ) cancer", 《J. CLIN. ONCO.》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022089377A1 (en) * 2020-10-26 2022-05-05 Taizhou Eoc Pharma Co., Ltd. Combination of a pd-1 or pd-l1 antagonist and a vegfr inhibitor for treating cancer

Also Published As

Publication number Publication date
EP3613746A4 (en) 2020-12-09
AU2018252643A1 (en) 2019-11-07
KR20190137116A (ko) 2019-12-10
EP3613746B1 (en) 2022-01-05
US10954246B2 (en) 2021-03-23
JP2020516685A (ja) 2020-06-11
CN110520425B (zh) 2023-04-14
CN107129502B (zh) 2022-08-05
CA3059455A1 (en) 2018-10-18
CN107129502A (zh) 2017-09-05
US20210171536A1 (en) 2021-06-10
EP3613746A1 (en) 2020-02-26
US20200071336A1 (en) 2020-03-05
WO2018188495A1 (zh) 2018-10-18

Similar Documents

Publication Publication Date Title
EP3269719B1 (en) Crystal form of jak inhibitor and preparation method thereof
TW201336497A (zh) 噻唑啶二酮化合物之結晶型及其製法
CN110092775B (zh) 靶向cdk4/6激酶抑制剂的晶型
CN110520425B (zh) EOC315 Mod.I晶型化合物及其制备方法
CN112010839B (zh) 靶向丝/苏氨酸激酶抑制剂的晶型
EP3279201B1 (en) Cdk inhibitor, eutectic crystal of mek inhibitor, and preparation method therefor
EP3747880B1 (en) Crystal form targeting cdk4/6 kinase inhibitor
WO2018139626A1 (ja) キナゾリン誘導体を含有する固形製剤
CN109476634B (zh) 喹唑啉衍生物的盐的晶体
CN101265275B (zh) 4-{6-[5-(2-氯-6-甲基苯胺甲酰基)-噻唑-2-氨基]-2-甲基嘧啶-4}-哌嗪-1-磷酸二乙酯
EP4495109A1 (en) Salt of substituted amino six-membered nitric heterocyclic compound, crystal form thereof, method for preparing same, and use thereof
CN108623601B (zh) 替莫唑胺和黄芩素的共晶及其制备方法
CN102245606A (zh) 新化合物
JP2023543281A (ja) アリールアミノキナゾリン含有化合物の塩、およびその製造方法と使用
US11111234B2 (en) Salt of a quinazoline derivative-like tyrosine kinase inhibitor and crystal form thereof
AU2015392050B2 (en) Fumarate of pyridylamine compound and crystals thereof
CN114681465B (zh) 洛铂-黄酮药物共晶及其制备方法和应用
CN114127071B (zh) 激酶抑制剂的多晶型、含有该化合物的药物组合物、制备方法、及应用
WO2021143819A1 (zh) 多环类间变性淋巴瘤激酶抑制剂的晶型
KR20230152118A (ko) 약물 조성물 및 이의 제조 방법 및 용도
CN106117199A (zh) 一种细胞周期蛋白依赖性激酶抑制剂的二羟乙基磺酸盐、其结晶形式及其制备方法
CN116063291A (zh) 一种杂环化合物马来酸盐的晶型
CN114051498A (zh) Pi3k抑制剂的结晶多晶型物及其制备方法
EA042455B1 (ru) Кристаллическая форма ингибитора, нацеленного на киназу cdk4/6
CN106061983A (zh) 吡嗪并[2,1‑c][1,2,4]三嗪化合物的晶体(1)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
CB02 Change of applicant information

Address after: 225300 building G24, No. 801, Jiankang Avenue, Taizhou City, Jiangsu Province

Applicant after: Taizhou Yiteng Jingang Pharmaceutical Co.,Ltd.

Address before: 225300 building G24, No. 801, Jiankang Avenue, Taizhou City, Jiangsu Province

Applicant before: Taizhou EOC Pharma Co.,Ltd.

CB02 Change of applicant information
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40010533

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant